The annual arc is defined by a single, persistent theme: the systematic expansion of the human proteome through non-canonical open reading frame (ncORF) translation. Led by the TransCODE Consortium's analysis of 95,520 proteomics experiments, the finding that ~25% of ncORFs produce peptides—yielding ~1,700 new microproteins and a novel 'peptidein' class—represents a structural rethinking of proteome boundaries. This narrative has consolidated from a fringe concept to a data-backed assertion, with public annotation tools signaling community adoption.

A regime-level shift is underway: the acceptance of ncORF translation as a legitimate source of functional peptides changes how the proteome is annotated and studied. This is not a quarterly anomaly but a durable alteration, as evidenced by the identical framing across successive briefs. The release of tools for community use indicates that the field is moving toward standardization.

Quiet build-ups include incremental advances in detection methodologies—from 2.5% peptide detection with trypsin to 24.6% with HLA immunopeptidomics—and the gradual refinement of computational tools. These technical underpinnings have enabled the main finding but received less emphasis than the discovery itself.

No major arcs ended; the story of ncORFs remained dominant throughout the year. Systemic omissions are notable: the briefs lack discussion of clinical translation pathways, regulatory implications, or potential artifacts. The silence on reproducibility and orthogonal validation methods (e.g., ribosome profiling) suggests a field focusing on discovery over application. This gap implies that therapeutic targeting of microproteins may be years away, and caution is warranted.

Overall, the year's trajectory is one of consolidation—a single powerful idea has moved from outlier to orthodoxy, but key translational and technical questions remain unaddressed.